(Circulation. 1999;99:2171-2176.)
© 1999 American Heart Association, Inc.
Basic Science Reports |
Role of Endothelin in Deterioration of Heart Failure Due to Cardiomyopathy in Hamsters
Increase in Endothelin-1 Production in the Heart and Beneficial Effect of Endothelin-A Receptor Antagonist on Survival and Cardiac Function
From Discovery Research Laboratory (R.Y.-K., T.H., H.A., H.Y., S.M.), Tanabe Seiyaku Co Ltd, Saitama, Japan; Department of Internal Medicine (T.M., T.K., S.S., Y.S.), Institute of Clinical Medicine; and Department of Pharmacology (K.G.), Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Japan.
Correspondence to Rikako Yamauchi-Kohno, MS, Discovery Research Laboratory, Tanabe Seiyaku Co Ltd, 2-2-50 Kawagishi, Toda, Saitama 335-8505, Japan. E-mail rikako-y{at}tanabe.co.jp
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—We previously reported that chronic endothelin (ET) receptor blockade ameliorated the survival rate and cardiac hemodynamics in rats with chronic heart failure (CHF) due to myocardial infarction. However, it remains unclear whether ET-1 is involved in the pathophysiology of cardiomyopathy, which is one of the major causes of CHF. Accordingly, we investigated the production of ET-1 in the heart and the effect of chronic ETA receptor blockade on survival rate and cardiac function in the Bio 14.6 hamster, which is an idiopathic model of CHF caused by cardiomyopathy.
Methods and Results—We used 52-week-old Bio 14.6 cardiomyopathic hamsters and age-matched F1b normal hamsters. The expression of preproET-1 mRNA and the ET-1 level in the hearts were markedly higher in the cardiomyopathic hamsters than in the normal hamsters. The cardiomyopathic hamsters showed severe CHF, illustrated by lower left ventricular (LV) +dP/dt/Pmax and right ventricular (RV) +dP/dt/Pmax and by higher LV end-diastolic pressure (EDP), RVEDP, and central venous pressure compared with the normal hamsters. Long-term (9 weeks) treatment with an ETA antagonist (TA-0201, 1.3 mg · kg-1 · d-1) markedly increased survival of cardiomyopathic hamsters (untreated, 16%; TA-0201–treated, 65.2%; P<0.001). After 6 weeks of treatment, LV +dP/dt/Pmax and RV +dP/dt/Pmax were significantly higher and LVEDP and RVEDP were lower in the TA-0201–treated group than in the untreated group, suggesting that chronic TA-0201 treatment effectively prevented deterioration of cardiac dysfunction.
Conclusions—In the cardiomyopathic hamsters with CHF, the production of ET-1 in the heart was markedly increased, and chronic ETA receptor blockade greatly ameliorated survival and cardiac dysfunction. These results suggest that ET-1 plays an important role in the deterioration of CHF caused by cardiomyopathy, and ETA antagonists may exert therapeutic effects in CHF due to cardiomyopathy.
Key Words: endothelin • cardiomyopathy • heart failure
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We and other groups have reported an increase in plasma levels of endothelin (ET)-1 in patients1 2 3 and experimental animals4 5 with chronic heart failure (CHF). It has been reported that plasma ET-1 level is a major predictor of mortality in patients with CHF.6 ET-1 is produced not only by endothelial cells7 but also by cardiac tissues, such as cardiac myocytes8 and fibroblasts.9 In cardiac myocytes, mechanical stretching10 and some neurohumoral factors (eg, angiotensin II and norepinephrine)11 12 stimulate the production of ET-1. Moreover, ET-1 has direct effects on contractile function,13 protein synthesis,14 15 and electrophysiological events16 17 in cardiac myocytes, and these effects are mediated primarily by ETA receptors. These observations suggest that increased ET-1 production and subsequent activation of ETA receptors contribute to the pathophysiological changes in CHF.
We previously reported that the plasma ET-1 level and production of ET-1 in the heart were markedly increased in CHF rats with myocardial infarction induced by coronary ligation.5 We also showed that long-term treatment with BQ-123, an ETA antagonist, greatly improved the survival rate of rats with CHF due to myocardial infarction.18 This beneficial effect of BQ-123 was accompanied by significant amelioration of left ventricular (LV) dysfunction and prevention of unfavorable ventricular remodeling.18
However, the pathogenesis of congestive heart failure is diverse. Not only ischemic heart disease, for which a coronary-ligated rat serves as a model, but also cardiomyopathy constitutes a primary part of the causes of CHF.19 Therefore, investigations of the roles of ET-1 in a cardiomyopathic CHF model are valuable to understand the efficacy and mechanism of ET antagonists for the treatment of CHF due to cardiomyopathy. The Bio 14.6 hamster, a model of idiopathic cardiomyopathy, is one of the representative models of CHF due to cardiomyopathy.20 The pathogenesis of the disease state is not fully understood, but this model spontaneously develops cardiac necrosis, hypertrophy, and finally progression to dilation and CHF in the later stages.20 Therefore, this model is appropriate for examining the effect of long-term treatment with drugs on the prognosis of CHF due to cardiomyopathy. However, either production of ET-1 in the heart or a role of ET-1 in the pathophysiology of this cardiomyopathic CHF model has not been investigated yet. We designed the present study to resolve these questions using an ETA receptor antagonist, TA-0201.21
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Study Protocols
We used male Bio 14.6 cardiomyopathic hamsters and F1b normal hamsters (Charles River, Yokohama, Japan). Hamsters were individually housed with a 12-hour light/dark cycle and received a powdered diet (CE-7, Nihon Clea) and tap water ad libitum.
In the present study, 2 series of experiments were performed. The aim of the first series of experiments was to investigate the levels of both preproET-1 mRNA and mature ET-1 peptide in the failing hearts of cardiomyopathic hamsters. The second series of experiments were performed to examine the effects of chronic treatment with an ETA antagonist on survival and cardiac function of cardiomyopathic hamsters. All experimental protocols for animal studies were approved by the Animal Care and Use Committee of Tanabe Seiyaku Co Ltd.
First Series of Experiments
Measurement of Cardiac Functions and Tissue Sampling
Measurements of cardiac functions were performed by a minor
modification of the method described previously.5 18 22
Bio 14.6 and F1b hamsters (52 weeks old) were anesthetized with
thiobutabarbital 100 mg/kg IP. A catheter (SP-10) was inserted into the
right carotid artery to measure arterial blood pressure and
was advanced into the LV for evaluating LV
+dP/dt/Pmax. Subsequently, another catheter was
inserted into the right jugular vein for the recording of
central venous pressure (CVP) and was advanced into the right ventricle
(RV) to measure RV +dP/dt/Pmax. After
measurements of cardiac functions, blood samples were collected and
stored at -80°C. The heart was excised and divided into the RV and
the LV including the septum. After each ventricle was weighed, all
samples were frozen in liquid nitrogen and stored at -80°C.
Sandwich Enzyme Immunoassay for Determination of Heart and Plasma
ET-1 Levels
The LV ET-1 level was determined as previously described in our
publications.5 18 22 Sandwich enzyme immunoassay (EIA) for
ET-1 was carried out with immobilized mouse monoclonal
antibody AwETN40, which recognizes the N-terminal portion of ET-1, and
peroxidase-labeled rabbit anti–ET-1 C-terminal peptide 15-21
Fab'.5 18 23 The assay for ET-1 did not cross-react with
ET-3 or big ET-1 (cross-reactivity <0.1%). Plasma ET-1 concentration
was also measured by a sandwich EIA.
Reverse Transcription and Polymerase Chain Reaction to Evaluate the
Level of PreproET-1 mRNA in the LV
Extraction of total RNA from the LV and analysis of
preproET-1 mRNA expression by reverse transcription and polymerase
chain reaction (RT-PCR) were performed as described
previously.24 Total RNA was reverse-transcribed by avian
myeloblastosis virus reverse transcriptase. The gene-specific primer
pair of preproET-1 was designed on the basis of the partial sequence of
hamster preproET-1.24 The expression of GAPDH mRNA was
also determined as an internal control. The gene-specific primer pair
of GAPDH was designed on the basis of the cDNA sequence for hamster
GAPDH.25 The sequences of the
oligonucleotides were as follows: preproET-1 (sense):
5'-CGAGCTGAGAATGAAGGGGAGAG-3'; preproET-1 (antisense):
5'-GCCTTTCTGCATGGTGTTTTGGGC-3'; GAPDH (sense):
5'-CCTCAACTACATGGTCTACA-3'; and GAPDH (antisense):
5'-CCTTCCACAATGCCAAAGTT-3'.
The reaction cycles of PCR were performed in a range that shows a linear correlation between the amount of cDNA and the yield of PCR products. The amplified PCR product was electrophoresed on a 1.2% agarose gel, stained with ethidium bromide, visualized by a UV transilluminator, and photographed. The photograph was scanned by a scanner (CanoScan 600; Canon) and quantified by computer with MacBAS software (Fuji Film).
Second Series of Experiments
Effect of TA-0201, an ETA Antagonist,
on Survival Rate of Cardiomyopathic Hamsters
Bio 14.6 hamsters (52 weeks old) were used in the study of
survival rate. Hamsters were randomized to receive either placebo
(n=25) or TA-0201 (n=24). TA-0201 was mixed into their diet at a
concentration of 30 ppm. The daily dose of TA-0201 in the treated group
was 
1.3 mg · kg-1 ·
d-1, and the plasma concentration of TA-0201 was
63.9±30.4 ng/mL (n=7). We reported that TA-0201 is an orally active
ETA antagonist.21 In the
binding study using human cloned ET receptors, TA-0201 showed higher
affinity for ETA receptors
(Ki=0.015 nmol/L) than for
ETB receptors (Ki=41
nmol/L).
Throughout the experiment, each hamster was inspected for signs of "wet tail," a fatal diarrhea in rodents that occurs frequently in hamsters. Hamsters that died of wet tail were excluded from the study. Based on these criteria, 1 of 56 cardiomyopathic hamsters was excluded during the course of the study.
Effect of TA-0201 on Cardiac Functions of Hamsters
We also evaluated the effect of chronic treatment with TA-0201
on cardiac functions of hamsters. Hamsters were randomized to receive
either placebo or TA-0201. Noncardiac death was observed in 1 animal
during the course of the study. After 6 weeks of treatment, all of the
surviving hamsters were anesthetized with thiobutabarbital 100
mg/kg IP, and cardiac functions were measured as described above.
Statistical Analysis
All data except the survival rate are expressed as mean±SEM.
Comparison of survival in untreated and TA-0201–treated
cardiomyopathic hamsters was analyzed by a
log-rank test with the Kaplan-Meier method. Plasma ET-1 levels in
cardiomyopathic and normal hamsters with or without
TA-0201 were examined by use of 2-way ANOVA with contrasts. The
analytical method used in other studies was the unpaired t
test. Differences were considered significant at the level of
P<0.05.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
First Series of Experiments
Cardiac Function and Tissue Weights
Table 1
shows mean blood
pressure (MBP), heart rate (HR), and cardiac functions measured in
anesthetized hamsters. In the 52-week-old
cardiomyopathic hamsters, MBP, HR, LV
+dP/dt/Pmax, and RV
+dP/dt/Pmax were significantly lower than in
age-matched normal hamsters. In addition, LV end-diastolic
pressure (LVEDP), RVEDP, and CVP were markedly elevated in the
cardiomyopathic hamsters. These data indicated that the
cardiomyopathic hamsters in 52 weeks had developed
severe cardiac dysfunction and CHF. LV and RV mass indices for body
weight (LV/BW and RV/BW) were much higher in the
cardiomyopathic hamsters than in the normal hamsters
(Table 1).
|
PreproET-1 mRNA Expression and Tissue ET-1 Level in the LV and
Plasma ET-1 Level
The expression of preproET-1 mRNA was markedly higher in
cardiomyopathic hamsters than in normal hamsters
(Figure 1). The values of band density of
PCR products for GAPDH mRNA did not differ between the 2 groups. As
shown in Figure 2A, the peptide ET-1
level in the LV of cardiomyopathic hamsters was
3.2-fold higher than that of normal hamsters. The plasma ET-1
concentration of the cardiomyopathic hamsters was also
1.7-fold higher than that of normal hamsters (Figure 2B).
Plasma ET-1 level was significantly correlated with LV
+dP/dt/Pmax (r=-0.81,
P<0.001) in the hamsters. The peptide level of ET-1 in the
LV was also significantly correlated with LV
+dP/dt/Pmax (r=-0.67,
P<0.01).
|
|
Second Series of Experiments
Effect of Chronic Administration of TA-0201 on Survival Rate of
Cardiomyopathic Hamsters
Chronic treatment with TA-0201 markedly increased the survival
rate of the cardiomyopathic hamsters (Figure 3). At the end of the experiment (after 9
weeks of treatment), the survival rates of
cardiomyopathic hamsters were 16% in the untreated
group and 65.2% in the TA-0201–treated group (Figure 3). The
survival rate of the treated group was significantly higher than that
of the untreated group (P<0.001).
|
Effect of Chronic Administration of TA-0201 on Cardiac Function and
Plasma ET-1 Levels in Cardiomyopathic Hamsters
Cardiac function was measured in anesthetized hamsters
after 6 weeks of treatment with or without TA-0201. At this point, the
survival rate of the TA-0201–treated cardiomyopathic
hamsters was significantly higher than that of the untreated hamsters
(82.6% versus 50%, P<0.05).
Chronic administration of TA-0201 did not affect MBP or HR in
cardiomyopathic hamsters (Figure 4). On the contrary, TA-0201–treated
hamsters showed significantly higher LV
+dP/dt/Pmax (Figure 4) and RV
+dP/dt/Pmax (Figure 5) compared with the untreated hamsters.
In addition, LVEDP (Figure 4), RVEDP (Figure 5), and CVP
(Figure 5) were significantly lower in the TA-0201–treated
compared with the untreated hamsters. With regard to the tissue
weights, RV/BW and lung/BW were also significantly lower in the
TA-0201–treated than in the untreated hamsters (Table 2).
|
|
|
In contrast to cardiomyopathic hamsters, TA-0201 showed no significant effects on hemodynamics and tissue weights in F1b hamsters (data not shown).
As shown in Figure 6, plasma ET-1 levels
were higher in the cardiomyopathic than in the normal
hamsters. TA-0201 did not affect plasma ET-1 levels in
cardiomyopathic and normal hamsters (Figure 6).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The present study clearly demonstrated that the production of ET-1 is markedly increased in the LV of Bio 14.6 cardiomyopathic hamsters at a stage of CHF. The chronic administration of an ETA antagonist, TA-0201, markedly improved the survival rate of cardiomyopathic hamsters. In addition, after 6 weeks of treatment, TA-0201 effectively prevented (1) the increase in LVEDP, RVEDP, and CVP; (2) the decrease in LV +dP/dt/Pmax and RV +dP/dt/Pmax; and (3) RV hypertrophy. These results suggest that chronic ET blockade improves the survival rate and ameliorates both LV and RV dysfunction in cardiomyopathic hamsters. Therefore, it is strongly suggested that endogenous ET-1 plays an important role in the deterioration of CHF due to cardiomyopathy in hamsters.
Cardiomyopathy, as well as myocardial infarction, is one of the major causes of CHF.19 It has been reported that plasma ET-1 level is increased in patients with cardiomyopathy.2 To date, however, the contribution of ET-1 in CHF caused by cardiomyopathy has not been investigated. Therefore, in the present study, we used Bio 14.6 cardiomyopathic hamsters (52 weeks old) to evaluate the role of ET-1 in CHF due to cardiomyopathy. At this age, not only plasma ET-1 concentration but also ET-1 production in the LV was significantly higher in the cardiomyopathic hamsters than in the age-matched normal hamsters, suggesting that ET pathway is activated in the cardiomyopathic hamsters. We also observed that LV +dP/dt/Pmax was markedly lower in the cardiomyopathic than in the normal hamsters. The LV +dP/dt/Pmax was negatively correlated with both plasma and LV ET-1 level in the hamsters. Plasma ET-1 concentration is well correlated with the clinical class of heart failure, New York Heart Association functional class in patients with chronic CHF.3 Taken together, the increased plasma ET-1 concentration in the cardiomyopathic hamsters may reflect the severity of cardiac dysfunction.
The long-term administration of an ETA antagonist, TA-0201, greatly improved survival of the cardiomyopathic hamsters. Indeed, the survival rate was 16% in the untreated cardiomyopathic hamsters and 65.2% in the TA-0201–treated hamsters. To the best of our knowledge, this is the first study to describe the beneficial effect of ET blockade on survival of cardiomyopathic hamsters at the CHF stage. We have already reported the beneficial effect of BQ-123, another ETA antagonist, in rats with CHF induced by coronary ligation.18 The administration of BQ-123 almost doubled the number of surviving rats with CHF; the survival rate of CHF rats treated with BQ-123 was 85%, compared with 43% for the untreated CHF rats.18 Therefore, ET antagonists may be beneficial for the treatment of CHF caused not only by ischemic heart disease but also by cardiomyopathy.
We observed that LV +dP/dt/Pmax and RV +dP/dt/Pmax were markedly lower in the 52-week-old cardiomyopathic hamsters than in the age-matched normal hamsters. Moreover, LVEDP, RVEDP, and CVP were markedly elevated in the cardiomyopathic hamsters compared with the normal hamsters. These results indicate that the cardiomyopathic hamsters at 52 weeks old already have severe cardiac dysfunction and are in an advanced stage of CHF. Therefore, the beneficial effect of TA-0201 on the survival rate of cardiomyopathic hamsters suggests that ETA antagonists have a therapeutic potential for CHF even when treatment is initiated at an advanced stage of CHF.
With regard to cardiac function, LV and RV performances in the untreated 58-week-old hamsters had progressively deteriorated compared with those in the 52-week-olds. The present study demonstrated that long-term treatment with TA-0201 significantly prevented the progression of cardiac dysfunction. Thus, these results suggest that ET-1 contributes to the progression of CHF due to cardiomyopathy and that these effects of an ETA antagonist on cardiac hemodynamics might favorably contribute to the prolongation of life expectancy in cardiomyopathic hamsters.
In this study, long-term treatment with TA-0201, an ETA antagonist, did not affect the arterial pressure in the cardiomyopathic hamsters. This result is in accordance with our previous data that the administration of BQ-123 did not alter the arterial pressure in rats with CHF due to myocardial infarction.18 However, Mulder et al26 and Fraccarollo et al27 reported that long-term treatment with bosentan, an ETA/ETB-nonselective antagonist, lowers arterial pressure in rats with CHF due to myocardial infarction. One possible explanation for the discrepancy in effects on arterial pressure among ET antagonists is that the blockade of both ETA and ETB receptors by bosentan contributes to hypotension, because both ETA- and ETB-mediated mechanisms for vascular contraction exist in various vessels. Indeed, in spontaneously hypertensive rats, bosentan lowers arterial pressure,28 whereas an ETA antagonist shows no significant effect.29
Furthermore, TA-0201 showed no significant effect on plasma ET-1 levels after 6 weeks of treatment in hamsters. Other investigators have demonstrated that ETA/B-nonselective antagonists, such as bosentan, increased plasma ET-1 and have suggested that this increase was partly attributed to the blockade of ETB receptor, which is considered to be involved in ET-1 clearance.30 31 Therefore, it is likely that long-term treatment with an ETA antagonist does not affect ET-1 clearance in hamsters.
We clearly indicated the beneficial effects of an ETA antagonist on survival rate and cardiac function, and the mechanisms for this improvement should be elucidated. First, because ET-1 has direct toxic effects on cardiac myocytes,32 an increase in ET-1 production in the heart may lead to myocardial injury and may contribute to the progression of CHF. Second, because ET-1 exerts a hypertrophic effect on cardiac myocytes,14 15 it is likely that the upregulated ET-1 system in the heart contributes to the excessive hypertrophy of myocardium in cardiomyopathic hamsters. Third, ET-1 is known to induce ventricular arrhythmia,33 and high arrhythmogenicity of the ventricles was reported in cardiomyopathic hamsters.34 Therefore, it is likely that the inhibition of ET-1–induced arrhythmia by ET antagonists is beneficial to increasing the survival rate. Fourth, because it was reported that the acute administration of some ET antagonists caused a moderate peripheral vasodilation in humans,35 we cannot exclude the possibility that the inhibition of ET-1–induced vasoconstriction partly contributes to the beneficial effects of the ETA antagonist.
In conclusion, our study demonstrates for the first time that (1) the production of ET-1 in the LV was greatly increased in the cardiomyopathic CHF hamsters, and (2) the chronic treatment with an ETA antagonist markedly improved the survival, cardiac function, and hypertrophy of cardiomyopathic hamsters with advanced CHF. These observations suggest that ET-1 contributes to the progression of CHF due to cardiomyopathy and that an ETA antagonist has therapeutic potential for CHF due to cardiomyopathy.
|
Acknowledgments |
|---|
This work was supported in part by a grant-in-aid for scientific research from the Ministry of Education, Science, Sports, and Culture of Japan (8670757, 9770473, 10670629) and a grant from the Miyauchi project of Tsukuba Advanced Research Alliance at the University of Tsukuba. The authors thank Noriko Ohashi for her excellent technical assistance.
|
Footnotes |
|---|
Guest Editor for this article was Michael R. Bristow, MD, University of Colorado Health Sciences Center, Denver.
Received May 13, 1998; revision received November 30, 1998; accepted December 18, 1998.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation. 1992;85:504–509.
2. Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, Tsujino M, Koike A, Nogami A, Takamoto T, Marumo F. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol. 1991;68:1114–1115.[Medline] [Order article via Infotrieve]
3.
Ishikawa S, Miyauchi T, Sakai S, Yamaguchi I,
Sugishita Y, Goto K. Elevated plasma endothelin-1 in young patients
with pulmonary hypertension due to congenital heart diseases is
decreased after successful surgical repair. J Thorac
Cardiovasc Surg. 1995;110:271–273.
4.
Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA,
Burnett JC Jr. Increased endothelin in experimental heart failure.
Circulation. 1990;82:2226–2230.
5.
Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M,
Yamaguchi I, Goto K, Sugishita Y. Endogenous endothelin-1
participates in the maintenance of cardiac function in rats
with congestive heart failure: marked increase in endothelin-1
production in the failing heart. Circulation. 1996;93:1214–1222.
6.
Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K.
Plasma endothelin determination as a prognostic indicator of 1-year
mortality after acute myocardial infarction. Circulation. 1994;89:1573–1579.
7. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, Yazaki Y, Goto K, Masaki T. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415.[Medline] [Order article via Infotrieve]
8. Suzuki T, Kumazaki T, Mitsui Y. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem Biophys Res Commun. 1993;191:823–830.[Medline] [Order article via Infotrieve]
9. Suzuki T, Tsuruda A, Katoh S, Kubodera A, Mitsui Y. Purification of endothelin from a conditioned medium of cardiac fibroblastic cells using beating rate assay of myocytes cultured in a serum-free medium. J Mol Cell Cardiol. 1997;29:2087–2093.[Medline] [Order article via Infotrieve]
10.
Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Hiroi
Y, Mizuno T, Maemura K, Kurihara H, Aikawa R, Takano H, Yazaki Y.
Endothelin-1 is involved in mechanical stress-induced
cardiomyocyte hypertrophy. J Biol
Chem. 1996;271:3221–3228.
11. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, Nogami A, Marumo F, Hiroe M. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest. 1993;92:398–403.
12.
Kaddoura S, Firth JD, Boheler KR, Sugden PH,
Poole-Wilson PA. Endothelin-1 is involved in
norepinephrine-induced ventricular
hypertrophy in vivo: acute effects of bosentan, an
orally active, mixed endothelin ETA and
ETB receptor antagonist.
Circulation. 1996;93:2068–2079.
13. Ishikawa T, Yanagisawa M, Kimura S, Goto K, Masaki T. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255(Heart Circ Physiol 24):H970–H973.
14.
Ito H, Hirata Y, Hiroe M, Tsujino M, Adachi S, Takamoto
T, Nitta M, Taniguchi K, Marumo F. Endothelin-1 induces
hypertrophy with enhanced expression of muscle-specific
genes in cultured neonatal rat cardiomyocytes. Circ
Res. 1991;69:209–215.
15.
Shubeita HE, McDonough PM, Harris AN, Knowlton KU,
Glembotski CC, Brown JH, Chien KR. Endothelin induction of inositol
phospholipid hydrolysis, sarcomere assembly, and cardiac gene
expression in ventricular myocytes: a paracrine mechanism
for myocardial cell hypertrophy. J Biol
Chem. 1990;265:20555–20562.
16. Ono K, Tsujimoto G, Sakamoto A, Eto K, Masaki T, Ozaki Y, Satake M. Endothelin-A receptor mediates cardiac inhibition by regulating calcium and potassium currents. Nature. 1994;370:301–304.[Medline] [Order article via Infotrieve]
17. Kobayashi S, Nakaya H, Takizawa T, Hara Y, Kimura S, Saito T, Masuda Y. Endothelin-1 partially inhibits ATP-sensitive K+ current in guinea pig ventricular cells. J Cardiovasc Pharmacol. 1996;27:12–19.[Medline] [Order article via Infotrieve]
18. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature. 1996;384:353–355.[Medline] [Order article via Infotrieve]
19. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J. 1991;121:1852–1853.[Medline] [Order article via Infotrieve]
20. Gertz EW. Cardiomyopathic Syrian hamster: a possible model of human disease. Prog Exp Tumor Res. 1972;16:242–260.[Medline] [Order article via Infotrieve]
21.
Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S.
Pharmacological profile of T-0201, a highly potent and orally active
endothelin receptor antagonist. J Pharmacol Exp
Ther. 1998;286:643–649.
22.
Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M,
Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K. Contribution of
endogenous endothelin-1 to the progression of
cardiopulmonary alterations in rats with monocrotaline-induced
pulmonary hypertension. Circ Res. 1993;73:887–897.
23. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K, Masaki T. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet. 1989;2:53–54.[Medline] [Order article via Infotrieve]
24. Miyauchi T, Kobayashi T, Yamauchi R, Hoshino T, Sakai S, Kikkawa K, Yabana H, Sugishita Y, Murata S, Goto K. Cloning of hamster preproendothelin-1 cDNA and its expression in the heart. J Cardiovasc Pharmacol. 1998;31(suppl I):S298–S301.
25.
Chang KW, Laconi S, Mangold KA, Hubchak S, Scarpelli
DG. Multiple genetic alteration in hamster pancreatic ductal
adenocarcinomas. Cancer Res. 1995;55:2560–2568.
26.
Mulder P, Richard V, Derumeaux G, Hogie M, Henry JP,
Lallemand F, Compagnon P, Macé B, Comoy E, Letac B, Thuillez C.
Role of endothelin in chronic heart failure: effect of long-term
treatment with an endothelin antagonist on survival,
hemodynamics, and cardiac remodeling.
Circulation. 1997;96:1976–1982.
27.
Fraccarollo D, Hu K, Galuppo P, Gaudron P, Ertl G.
Chronic endothelin receptor blockade attenuates progressive
ventricular dilation and improves cardiac function in rats
with myocardial infarction: possible involvement of myocardial
endothelin system in ventricular remodeling.
Circulation. 1997;96:3963–3973.
28. Clozel M, Clozel JP, Hess P. Endothelin receptor antagonism: a new therapeutic approach in experimental hypertension. Circulation. 1993;88(suppl I):I-316. Abstract.
29. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M, Ishikawa K, Ikemoto F. Antihypertensive effect of a newly synthesized endothelin antagonist, BQ-123, in a genetic hypertensive model. Life Sci. 1993;52:717–724.[Medline] [Order article via Infotrieve]
30. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating endothelin-1 by ETB receptors in rats. Biochem Biophys Res Commun. 1994;199:1461–1465.[Medline] [Order article via Infotrieve]
31.
Dupuis J, Goresky CA, Fournier A. Pulmonary
clearance of circulating endothelin-1 in dogs in vivo:
exclusive role of ETB receptors. J
Appl Physiol. 1996;81:1510–1515.
32. Prasad MR. Endothelin stimulates degradation of phospholipids in isolated rat hearts. Biochem Biophys Res Commun. 1991;174:952–957.[Medline] [Order article via Infotrieve]
33. Yorikane R, Koike H. The arrhythmogenic action of endothelin in rats. Jpn J Pharmacol. 1990;53:259–263.[Medline] [Order article via Infotrieve]
34.
Hano O, Mitsuoka T, Matsumoto Y, Ahmed R, Hirata M,
Hirata T, Mori M, Yano K, Hashida K. Arrhythmogenic properties of the
ventricular myocardium in
cardiomyopathic Syrian hamster, Bio 14.6 strain.
Cardiovasc Res. 1991;25:49–57.
35. Kiowski W, Sütsch G, Hunziker P, Müller P, Kim J, Oechslin E, Schmitt R, Jones R, Bertel O. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet. 1995;6:732–736.
This article has been cited by other articles:
 |
|
 |
|
  N. Shimojo, S. Jesmin, S. Zaedi, T. Otsuki, S. Maeda, N. Yamaguchi, K. Aonuma, Y. Hattori, and T. Miyauchi Contributory role of VEGF overexpression in endothelin-1-induced cardiomyocyte hypertrophy Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H474 - H481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kang, K. Y. Chung, and J. W. Walker G-Protein Coupled Receptor Signaling in Myocardium: Not for the Faint of Heart Physiology, June 1, 2007; 22(3): 174 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Iemitsu, S. Maeda, T. Otsuki, K. Goto, and T. Miyauchi Time Course Alterations of Myocardial Endothelin-1 Production During the Formation of Exercise Training-Induced Cardiac Hypertrophy Exp Biol Med, June 1, 2006; 231(6): 871 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Davis, G. Valacchi, E. Pagnin, Q. Shao, H. B. Gross, L. Calo, and W. Yokoyama Walnuts Reduce Aortic ET-1 mRNA Levels in Hamsters Fed a High-Fat, Atherogenic Diet J. Nutr., February 1, 2006; 136(2): 428 - 432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Honore, M.-H. Fecteau, I. Brochu, J. Labonte, G. Bkaily, and P. D'Orleans-Juste Concomitant antagonism of endothelial and vascular smooth muscle cell ETB receptors for endothelin induces hypertension in the hamster Am J Physiol Heart Circ Physiol, September 1, 2005; 289(3): H1258 - H1264. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Ogata, T. Miyauchi, S. Sakai, M. Takanashi, Y. Irukayama-Tomobe, and I. Yamaguchi Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-b pathway J. Am. Coll. Cardiol., April 21, 2004; 43(8): 1481 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Yang, R. Gros, M. G. Kabir, A. Sadi, A. I. Gotlieb, M. Husain, and D. J. Stewart Conditional Cardiac Overexpression of Endothelin-1 Induces Inflammation and Dilated Cardiomyopathy in Mice Circulation, January 20, 2004; 109(2): 255 - 261. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Kedzierski, P. A. Grayburn, Y. Y. Kisanuki, C. S. Williams, R. E. Hammer, J. A. Richardson, M. D. Schneider, and M. Yanagisawa Cardiomyocyte-Specific Endothelin A Receptor Knockout Mice Have Normal Cardiac Function and an Unaltered Hypertrophic Response to Angiotensin II and Isoproterenol Mol. Cell. Biol., November 15, 2003; 23(22): 8226 - 8232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Berger and R Pacher The role of the endothelin system in myocardial infarction--new therapeutic targets? Eur. Heart J., February 2, 2003; 24(4): 294 - 296. [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, H. Boujedaini, V. Richard, J.-P. Henry, S. Renet, K. Munter, and C. Thuillez Long-Term Survival and Hemodynamics After Endothelin-A Receptor Antagonism and Angiotensin-Converting Enzyme Inhibition in Rats With Chronic Heart Failure: Monotherapy Versus Combination Therapy Circulation, August 27, 2002; 106(9): 1159 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsumoto, H. Aihara, R. Yamauchi-Kohno, Y. Reien, T. Ogura, H. Yabana, Y. Masuda, T. Sato, I. Komuro, and H. Nakaya Long-Term Endothelin A Receptor Blockade Inhibits Electrical Remodeling in Cardiomyopathic Hamsters Circulation, July 30, 2002; 106(5): 613 - 619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Ueno, T. Miyauchi, S. Sakai, R. Yamauchi-Kohno, K. Goto, and I. Yamaguchi A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats J. Am. Coll. Cardiol., July 3, 2002; 40(1): 175 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. V Agapitov and W. G Haynes Role of endothelin in cardiovascular disease Journal of Renin-Angiotensin-Aldosterone System, March 1, 2002; 3(1): 1 - 15. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Iemitsu, T. Miyauchi, S. Maeda, S. Sakai, T. Kobayashi, N. Fujii, H. Miyazaki, M. Matsuda, and I. Yamaguchi Physiological and pathological cardiac hypertrophy induce different molecular phenotypes in the rat Am J Physiol Regulatory Integrative Comp Physiol, December 1, 2001; 281(6): R2029 - R2036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-M. Herrmann, K. Schmidt-Petersen, J. Pfeifer, A. Perrot, N. Bit-Avragim, C. Eichhorn, R. Dietz, R. Kreutz, M. Paul, and K.J. Osterziel A polymorphism in the endothelin-A receptor gene predicts survival in patients with idiopathic dilated cardiomyopathy Eur. Heart J., October 2, 2001; 22(20): 1948 - 1953. [Abstract] [PDF]
|
|
|
|
|
|
Y. Kakinuma, T. Miyauchi, K. Yuki, N. Murakoshi, K. Goto, and I. Yamaguchi Novel Molecular Mechanism of Increased Myocardial Endothelin-1 Expression in the Failing Heart Involving the Transcriptional Factor Hypoxia-Inducible Factor-1{{alpha}} Induced for Impaired Myocardial Energy Metabolism Circulation, May 15, 2001; 103(19): 2387 - 2394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki and T. Miyauchi A novel pharmacological action of ET-1 to prevent the cytotoxicity of doxorubicin in cardiomyocytes Am J Physiol Regulatory Integrative Comp Physiol, May 1, 2001; 280(5): R1399 - R1406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. F. Luscher and M. Barton Endothelins and Endothelin Receptor Antagonists : Therapeutic Considerations for a Novel Class of Cardiovascular Drugs Circulation, November 7, 2000; 102(19): 2434 - 2440. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Rothermund, Y. M. Pinto, B. Hocher, R. Vetter, S. Leggewie, P. Ko{beta}mehl, H.-D. Orzechowski, R. Kreutz, and M. Paul Cardiac Endothelin System Impairs Left Ventricular Function in Renin-Dependent Hypertension via Decreased Sarcoplasmic Reticulum Ca2+ Uptake Circulation, September 26, 2000; 102(13): 1582 - 1588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Mulder, H. Boujedaini, V. Richard, G. Derumeaux, J. P. Henry, S. Renet, J. Wessale, T. Opgenorth, and C. Thuillez Selective Endothelin-A Versus Combined Endothelin-A/Endothelin-B Receptor Blockade in Rat Chronic Heart Failure Circulation, August 1, 2000; 102(5): 491 - 493. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sakai, T. Miyauchi, and I. Yamaguchi Long-Term Endothelin Receptor Antagonist Administration Improves Alterations in Expression of Various Cardiac Genes in Failing Myocardium of Rats With Heart Failure Circulation, June 20, 2000; 101(24): 2849 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. N. Serneri, I. Cecioni, S. Vanni, R. Paniccia, B. Bandinelli, A. Vetere, X. Janming, I. Bertolozzi, M. Boddi, G. F. Lisi, et al. Selective Upregulation of Cardiac Endothelin System in Patients With Ischemic but Not Idiopathic Dilated Cardiomyopathy : Endothelin-1 System in the Human Failing Heart Circ. Res., March 3, 2000; 86(4): 377 - 385. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||